Literature DB >> 29610508

ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Gary R Lichtenstein1, Edward V Loftus2, Kim L Isaacs3, Miguel D Regueiro4, Lauren B Gerson5, Bruce E Sands6.   

Abstract

Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn's disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn's disease has evolved since the last practice guideline was published. These guidelines represent the official practice recommendations of the American College of Gastroenterology and were developed under the auspices of the Practice Parameters Committee for the management of adult patients with Crohn's disease. These guidelines are established for clinical practice with the intent of suggesting preferable approaches to particular medical problems as established by interpretation and collation of scientifically valid research, derived from extensive review of published literature. When exercising clinical judgment, health-care providers should incorporate this guideline along with patient's needs, desires, and their values in order to fully and appropriately care for patients with Crohn's disease. This guideline is intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated. To evaluate the level of evidence and strength of recommendations, we used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The Committee reviews guidelines in depth, with participation from experienced clinicians and others in related fields. The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29610508     DOI: 10.1038/ajg.2018.27

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  358 in total

1.  Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease.

Authors:  Alexandra Gutierrez; Hang Lee; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2006-10       Impact factor: 10.864

2.  IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease.

Authors:  Rebecca L Roberts; Richard B Gearry; Jade E Hollis-Moffatt; Allison L Miller; Julia Reid; Victor Abkevich; Kirsten M Timms; Alexander Gutin; Jerry S Lanchbury; Tony R Merriman; Murray L Barclay; Martin A Kennedy
Journal:  Am J Gastroenterol       Date:  2007-09-25       Impact factor: 10.864

3.  Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.

Authors:  Konstantinos Papamichael; Emmanuel Archavlis; Constantina Lariou; Gerassimos J Mantzaris
Journal:  J Crohns Colitis       Date:  2012-03-15       Impact factor: 9.071

4.  Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

Authors:  R Caprilli; M Cottone; F Tonelli; G Sturniolo; F Castiglione; V Annese; C Papi; A Viscido; C Cammà; G Corrao; G Latella
Journal:  Aliment Pharmacol Ther       Date:  2003-02-15       Impact factor: 8.171

5.  Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.

Authors:  R Löfberg; P Rutgeerts; H Malchow; C Lamers; A Danielsson; G Olaison; D Jewell; O Ostergaard Thomsen; H Lorenz-Meyer; H Goebell; H Hodgson; T Persson; C Seidegård
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 6.  The toxicity of methotrexate in male fertility and paternal teratogenicity.

Authors:  Jennifer Christine Gutierrez; Kathleen Hwang
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-09-09       Impact factor: 4.481

7.  Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.

Authors:  J R Goodhand; M Wahed; J E Mawdsley; A D Farmer; Q Aziz; D S Rampton
Journal:  Inflamm Bowel Dis       Date:  2012-02-22       Impact factor: 5.325

8.  Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.

Authors:  Mariam Aguas; Guillermo Bastida; Elena Cerrillo; Belén Beltrán; Marisa Iborra; Cristina Sánchez-Montes; Fernando Muñoz; Jesús Barrio; Sabino Riestra; Pilar Nos
Journal:  World J Gastroenterol       Date:  2012-08-28       Impact factor: 5.742

Review 9.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

10.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

View more
  242 in total

1.  Heparin-Coated Albumin Nanoparticles for Drug Combination in Targeting Inflamed Intestine.

Authors:  Sufeng Zhang; Won Joon Cho; Amy T Jin; Lie Yun Kok; Yunhua Shi; David E Heller; Young-Ah Lucy Lee; Yixuan Zhou; Xi Xie; Joshua R Korzenik; Jochen K Lennerz; Giovanni Traverso
Journal:  Adv Healthc Mater       Date:  2020-06-29       Impact factor: 9.933

2.  Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease.

Authors:  Sara Lewin; Fernando S Velayos
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-09

Review 3.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

4.  Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm.

Authors:  Suruchi Batra; Laurie S Conklin
Journal:  Handb Exp Pharmacol       Date:  2020

Review 5.  A product review of vedolizumab in inflammatory bowel disease.

Authors:  Robert Battat; Parambir S Dulai; Vipul Jairath; Niels Vande Casteele
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

6.  Highlights From the New ACG Guideline on Crohn's Disease Management.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-08

Review 7.  Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence.

Authors:  Andrew T Weber; Neha D Shah; Jenny Sauk; Berkeley N Limketkai
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 8.  A Comprehensive Review of the Diagnosis and Pharmacological Management of Crohn's Disease in the Elderly Population.

Authors:  David Kim; Sasha Taleban
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 9.  Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape.

Authors:  Elyse A Linson; Stephen B Hanauer
Journal:  Curr Gastroenterol Rep       Date:  2021-08-02

Review 10.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.